by Safe RX Compounding | Aug 26, 2026 | Featured
By Philip J. Schneider and Ronald P. Jordan Patients deserve innovation, but they also deserve evidence. FDA should not allow pharmacy compound-ing to become a shortcut around safety and efficacy standards that protect the public. If compounding becomes an entry point...
by Safe RX Compounding | Aug 26, 2026 | Featured
Author(s)Habiba Atta Fact checked by: Laura Joszt, MA FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist. When a reconstituted FDA advisory panel voted in late July to recommend...
by Safe RX Compounding | May 23, 2026 | Featured
Interest in next-generation obesity medicines is accelerating rapidly — and so is the online marketplace claiming to sell them. One of the latest examples is retatrutide, an investigational therapy currently being studied in clinical trials but increasingly promoted...
by Safe RX Compounding | May 4, 2026 | Featured
Philip Schneider, MS FASHP FFIP As a pharmacist, my priority is helping patients benefit from medicines, and protect them from harm caused by medicines intended to help them. This week we saw an example of why the oversight of the U.S. Food and Drug Administration...
by Safe RX Compounding | May 4, 2026 | Featured
Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 Washington, DC – You can fool some of the people some of the time and all of the people some of the time. But you can’t fool all of the people all the time. On Friday, February 6, the Food...
